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Abstract: Blood-brain barrier (BBB) impairment clearly accelerates brain disease progression. As ways
to prevent injury-induced barrier dysfunction remain elusive, better understanding of how BBB cells
interact and modulate barrier integrity is needed. Our metabolomic profiling study showed that cell-
specific adaptation to injury correlates well with metabolic reprogramming at the BBB. In particular
we noted that primary astrocytes (AC) contain comparatively high levels of glutathione (GSH)-related
metabolites compared to primary endothelial cells (EC). Injury significantly disturbed redox balance in
EC but not AC motivating us to assess 1) whether an AC-EC GSH shuttle supports barrier stability and
2) the impact of GSH on EC function. Using an isotopic labeling/tracking approach combined with Time-
of-Flight Mass Spectrometry (TOF-MS) we prove that AC constantly shuttle GSH to EC even under
resting conditions - a flux accelerated by injury conditions in vitro. In correlation, co-culture studies
revealed that blocking AC GSH generation and secretion via siRNA-mediated ฀-glutamyl cysteine ligase
(GCL) knockdown significantly compromises EC barrier integrity. Using different GSH donors, we further
show that exogenous GSH supplementation improves barrier function by maintaining organization of
tight junction proteins and preventing injury-induced tight junction phosphorylation. Thus the AC GSH
shuttle is key for maintaining EC redox homeostasis and BBB stability suggesting GSH supplementation
could improve recovery after brain injury.
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ABSTRACT  26 
Blood-brain barrier (BBB) impairment clearly accelerates brain disease progression. As ways to 27 
prevent injury-induced barrier dysfunction remain elusive, better understanding of how BBB cells 28 
interact and modulate barrier integrity is needed. Our metabolomic profiling study showed that cell-29 
specific adaptation to injury correlates well with metabolic reprogramming at the BBB. In particular 30 
we noted that primary astrocytes (AC) contain comparatively high levels of glutathione (GSH)-31 
related metabolites compared to primary endothelial cells (EC). Injury significantly disturbed redox 32 
balance in EC but not AC motivating us to assess 1) whether an AC-EC GSH shuttle supports 33 
barrier stability and 2) the impact of GSH on EC function. Using an isotopic labeling/tracking 34 
approach combined with Time-of-Flight Mass Spectrometry (TOF-MS) we prove that AC constantly 35 
shuttle GSH to EC even under resting conditions - a flux accelerated by injury conditions in vitro. In 36 
correlation, co-culture studies revealed that blocking AC GSH generation and secretion via siRNA-37 
mediated γ-glutamyl cysteine ligase (GCL) knockdown significantly compromises EC barrier 38 
integrity. Using different GSH donors, we further show that exogenous GSH supplementation 39 
improves barrier function by maintaining organization of tight junction proteins and preventing 40 
injury-induced tight junction phosphorylation. Thus the AC GSH shuttle is key for maintaining EC 41 
redox homeostasis and BBB stability suggesting GSH supplementation could improve recovery 42 
after brain injury. 43 
 44 
 45 
SIGNIFICANCE  46 
Improving brain vascular function to accelerate disease recovery remains an unmet medical need. 47 
Here we show that astrocyte (AC)-derived glutathione (GSH) plays a strategic role in endothelial 48 
(EC) stability by suppressing EC tight junction phosphorylation and delocalization. Importantly, 49 
blocking AC GSH shuttling disrupts the endothelial barrier resulting in increased permeability. Thus 50 
maintaining this transfer during injury scenarios is critical. Our data provides significant insight into 51 
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(patho)physiological metabolic BBB regulation and suggests GSH treatment may be an effective 52 




Vascular health underlies proper physiological function. Early blood-brain barrier (BBB) breakdown 57 
and/or dysfunction occurs in many neurological diseases, and significantly contributes to disease 58 
progression [1–3]. Multiple studies suggest that stabilizing brain vascular function in patients with 59 
neurological disease could arrest or even reverse the course of brain disorders [2], but ways to 60 
attain this goal remain elusive. Highly specialized endothelial cells (EC) that are in close contact 61 
with perivascular astrocytes and pericytes, form the inner wall of brain microvessels. The 62 
stabilization of EC tight junction complexes mediates barrier tightness and restricts the passage of 63 
substances to and from the bloodstream thus maintaining cerebral ion and metabolic balance [3,4]. 64 
We are convinced that better understanding of how perivascular cells regulate both physiological 65 
and pathological EC responses will provide valuable insight into how to modulate BBB functionality.  66 
Astrocyte (AC) endfeet ensheath brain microvessels as well as connect to neurons thus functioning 67 
as regulators of different cellular compartments. Direct contact between AC and neurons allows 68 
exchange of multiple substances that sustain neuronal survival and function. An important example 69 
is the release of supportive metabolites such as glutathione (GSH) and glutamine. GSH is a critical 70 
antioxidant in the brain that maintains cellular oxidative homeostasis [5]. GSH metabolic crosstalk 71 
rapidly contributes to maintaining neuronal redox homeostasis [6], supporting neurotransmitter 72 
recycling [7,8] and regulating neuronal gene expression programs [9]. In contrast, little is known of 73 
how metabolites impact BBB integrity [4], but it seems logical that a similar AC-EC crosstalk could 74 
also support barrier function. 75 
We previously performed metabolomic profiling of primary AC and EC to obtain detailed insight into 76 
cell-specific regulation of critical pathways during resting and different injury conditions (Huang et 77 
al, in press). A number of metabolites and pathways that were reduced in EC but elevated or 78 
stabilized in AC during injury were identified. We considered that AC secretion of such metabolites, 79 
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especially those known to facilitate cell survival or adaptation to adverse situations, could be key in 80 
supporting EC function. GSH was of particular interest due to its critical anti-oxidant role and the 81 
fact that GSH-deficiency has already been observed in many BBB impairment-associated brain 82 
diseases in patients [10,11]. GSH deficit was also shown to induce barrier leakage in a rat model 83 
[12] and its administration prevented endothelial oxidative imbalance in vitro [13,14]. 84 
We hypothesized that GSH is critical for brain vascular function and its secretion by AC promotes 85 
BBB stability during injury conditions i.e. when EC GSH generation is impeded. Using an isotopic 86 
labeling/tracking approach combined with Time-of-Flight Mass Spectrometry (TOF-MS) we prove 87 
that AC secreted GSH is constantly shuttled to EC, and this flux is accelerated by injury conditions. 88 
Next, we demonstrate that GSH synthesis-deficient AC (via siRNA-mediated γ-glutamyl cysteine 89 
ligase knockdown) lose their ability to protect the barrier under injury conditions. Finally, in the 90 
absence of AC, sole GSH supplementation abrogates injury-induced EC permeability. Taken 91 
together, better insight of metabolic shuttling and reprogramming may provide innovative ways to 92 




Changes in glutathione-related metabolites during injury conditions  97 
In a previous study we used untargeted LC-MS to obtain comprehensive metabolomic profiles of 98 
primary rat brain microvascular endothelial cells (EC) and primary rat astrocytes (AC) exposed to 99 
different conditions (Huang et al. in press). Samples were collected and extracted after 24h 100 
normoxia (Nx), hypoxia (Hx) or near anoxia (Ax) in media with or without glucose (±Glc) to simulate 101 
ischemia in vitro. We noted that regulation of key metabolites of the GSH pathway was quite 102 
different in the two cell types. A comparison relative to the baseline (Nx) composition of each cell is 103 
shown in a heatmap with increased and decreased metabolites indicated in red and blue 104 
respectively (Fig. 1A). Major metabolites supporting GSH synthesis such as cysteine and glycine 105 
were clearly more abundant in AC (Fig.1A). Furthermore, cellular GSH and GSH disulfide levels 106 
were overrepresented in AC compared to EC (Fig.1A).  107 
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Next we investigated how injury modulates cellular GSH metabolism in AC and EC by comparing 108 
the injury profiles with Nx baseline conditions. Heat maps show oxygen and glucose deprivation 109 
stimulate AC GSH metabolic activity whereas a clear reduction occurs in EC (Fig.1B). Interestingly, 110 
under the most severe injury condition (0.2% O2 without glucose) GSH and glycine were strongly 111 
reduced in AC, whereas γ-glutamyl-cysteine, a precursor that determines the GSH synthesis rate 112 
[15], remained high. This implies that AC maintain GSH metabolism even during severe conditions. 113 
In complete contrast, EC GSH metabolism was diminished under virtually all conditions and 114 
particularly in the absence of glucose. We directly compared levels of three GSH activity indicators 115 
in AC and EC during hypoxia (1% O2 with glucose) and oxygen and glucose deprivation (OGD) i.e. 116 
1% O2 without glucose (Fig 1C-E). At baseline both cells displayed similar amounts of the 117 
intermediate product γ-glutamyl-cysteine with an injury-induced reduction observed only in EC (Fig. 118 
1C). Much higher levels of the end products GSH and GSH disulfide were consistently measured in 119 
AC (Fig. 1D and E) with EC GSH levels strongly reduced during OGD (Fig. 1D). Thus AC have 120 
comparatively better stores and greater capacity to generate/use GSH in injury situations.  121 
 122 
Oxidative homeostasis is stable in AC but not EC 123 
GSH efficiently maintains cellular redox balance [5]. To know whether the redox equilibrium of AC 124 
and EC correlated with their GSH metabolic activity, we measured reactive oxygen species (ROS) 125 
levels for 48 hours in hypoxic and ischemic cells. Within 4h hypoxia induced a 3-fold increase in 126 
AC ROS activity that returned to normoxic baseline by 48h (Fig. 2A). Intriguingly, the severest 127 
condition of oxygen and glucose withdrawal in AC had less dramatic effects on ROS levels and 128 
never reached those of hypoxic values (Fig. 2A). In contrast, ROS accumulation in EC (Fig. 2B) 129 
was insult severity-dependent with OGD inducing higher ROS levels than hypoxia. Notably OGD-130 
induced ROS accumulation in EC began only after 6 hours and remained consistently elevated by 131 
2-4 fold at 48h compared to Nx baseline (Fig 2B). These results highlight a cell-specific and time-132 
dependent modulation of redox balance during injury conditions.  133 
 134 
Injury increases GSH secretion by AC  135 
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Since secretion of GSH and its related metabolites by AC could benefit EC in addition to neurons in 136 
vivo we assessed AC intracellular and extracellular GSH levels during normoxia, hypoxia and OGD 137 
for up to 24h. Interestingly, endogenous GSH levels were consistently maintained at normoxic 138 
levels with OGD tending to increase the quantities (Fig. 3A). Extracellularly a time- and injury-139 
dependent increase of more than two-fold was noted compared to normoxic conditions (Fig. 3B). 140 
Thus injury conditions stimulate GSH secretion but do not alter endogenous homeostasis 141 
consistent with GSH associated pathways being constantly active and modulated in AC during 142 
injury situations (Fig. 1B). To date, a GSH-specific exporter has not been identified but multidrug 143 
resistance proteins (MRP) are considered to be the major transporter family involved in GSH 144 
secretion [16]. In this regard injury-induced AC MRP2 mRNA (Supplementary information Fig. S1A) 145 
and protein expression was observed (Supplementary information Fig. S1B) whereas MRP1 and 146 
MRP4 expression was unchanged (data not shown). Gamma glutamyl transpeptidase (GGT) plays 147 
a key role in extracellular GSH catabolism and supporting intracellular oxidative stress 148 
homeostasis. We observed that messenger RNA levels of GGT were strongly induced during 149 
hypoxia and particularly OGD (Supplementary information Fig. S1C) but no change in protein 150 
levels was detected (Supplementary information Fig. S1D). 151 
 152 
GSH is constantly shuttled from AC to EC  153 
To investigate if EC take up the GSH secreted by AC, a stable isotope labeling approach combined 154 
with TOF-MS was used to monitor its movement. As cysteine is an essential GSH building block, 155 
34S15N-cysteine (Cys) isotope was incorporated into AC GSH molecules as schematically depicted 156 
(Fig. 4A). First, endogenous GSH levels were depleted by culturing AC in methionine/cysteine-free 157 
culture media for 24h. Subsequently the AC were incubated in 34S15N-Cys-containing media for 24h 158 
to boost biosynthesis of endogenously labeled 34S15N-GSH. The ratios of ion intensities of GSH 159 
(considering both mass accuracy and TOF resolution) were compared in AC treated with and 160 
without 34S15N-Cys. Using an annotation depicting the abundance of isotopes, M is natural GSH 161 
monoisotopic mass and M+3 is enriched metabolite which is three Daltons heavier than the 162 
monoisotopic GSH. The M+3/M ratio, corresponding to the natural isotopic abundance in the 163 
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baseline samples,  is expected to increase in samples treated with the isotope (due to the inclusion 164 
of labeled GSH in the cellular GSH pool). Accordingly, the natural abundance of labeled GSH 165 
(M+3/M) was 6-7% in cells not incubated in 34S15N-Cys and exceeded 135% after 24h stimulation 166 
confirming successful incorporation into the intracellular GSH pool (Fig. 4B). Next, to test our 167 
hypothesis that AC-derived GSH is shuttled to EC, we co-cultured labeled AC with EC in 168 
TranswellsTM [17] prior to 24h injury exposure (Fig. 4A). Samples from the different compartments 169 
were then collected and analyzed to assess if transfer occurred. Interestingly, intracellular levels of 170 
labeled GSH in both mono- and co-cultured AC lysates always corresponded to baseline values 171 
(6% to 8%), suggesting extended exposure results in metabolic dilution of the M+3 enrichment 172 
(Supplementary information Fig. S2). Unexpectedly, measurement of EC intracellular metabolites 173 
after normoxic (Nx) co-culture showed labeled GSH levels were increased by up to 2-fold 174 
compared to baseline within 24h. Thus metabolic shuttling exists in the absence of injury (Fig. 4C). 175 
Injury exposure further expedited enrichment of labeled GSH (Fig. 4C) demonstrating increased 176 
paracrine crosstalk. Notably, GSH shuttling occurs even during harshest conditions as levels 177 
similar to normoxia were maintained during severe OGD (Ax-Glc) (Fig. 4C). Thus GSH shuttling 178 
between AC and EC is constantly active.  179 
 180 
Paracrine GSH shuttling is crucial for barrier maintenance during injury  181 
To prove GSH shuttling supports barrier function, we employed siRNA to silence γ-glutamyl 182 
cysteine ligase (GCL) gene and disrupt the rate limiting step of GSH synthesis [5]. Post siGCL 183 
transfection, protein levels were significantly reduced (Fig. 5A) and GSH secretion rate was 184 
successfully reduced by 10-20% compared to untreated controls (Fig. 5B). GSH-deficient AC were 185 
then co-cultured with primary EC on TranswellsTM and exposed to hypoxic/OGD for 48h. Barrier 186 
function was measured by lucifer yellow flux. In agreement with their barrier supportive role [4,17], 187 
co-culture of EC with untreated (UNT) AC prevented injury-induced barrier leakage (Fig. S3). 188 
Remarkably, when co-cultured with GSH-deficient AC (siGCL) significantly increased paracellular 189 
flux was measured under both injury conditions compared to siCTRL (Fig. 5C). Thus impeding 190 
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GSH shuttling compromises AC protective effects and directly impairs the ability of EC to maintain 191 
their barrier function. Clearly the shuttle reinforces barrier stability.  192 
 193 
Boosting EC GSH levels prevents injury-induced BBB breakdown 194 
As EC GSH metabolism is increasingly shutdown during injury, we asked if barrier impairment can 195 
be prevented by providing the metabolite exogenously. Permeability of confluent primary EC 196 
monolayers treated with GSH compounds prior to hypoxic/ischemic exposure for 48h was 197 
measured. In untreated samples the degree of barrier permeability correlated with injury severity 198 
(Fig. 6A and B) as expected. Excitingly, enhancing GSH levels using GSHee and NAC prevented 199 
barrier leakage not only in hypoxia but also during OGD (Fig. 6A and B). Notably, GSHee 200 
maintained the BBB as tight as the normoxic controls in both injury conditions. The GSH synthesis 201 
inhibitor (BSO) showed no additional negative effect compared to controls (UNT, Fig. 6A and B).  202 
Using immunostaining we next tested if exogenous GSH improved BBB stability by suppressing 203 
injury-induced tight and adherens junction delocalization. As expected, injury severity progressively 204 
disrupted junctional localization at cell-cell borders as observed by discontinuous and frayed 205 
organization of claudin-5 (arrows, Fig. 6C) and occludin (data not shown) in hypoxic cells 206 
compared to normoxic controls. Injury also disrupted β-catenin retention at cell-cell borders (arrows, 207 
Fig. 6D). Overall during injury the cells lost both morphology and close organization with gaps 208 
increasingly visualized (asterisks). Consistent with the functional data, GSH enhancers prevented 209 
tight and adherens junction disruption in both injury conditions although NAC was consistently less 210 
effective than GSHee (Fig. 6C and D). Thus boosting cellular GSH levels prevents barrier 211 
impairment (without impacting cell survival, Supplementary information Fig. S4).  212 
 213 
Exogenous GSH suppresses occludin tyrosine phosphorylation 214 
The post-transcriptional modification of tight junction proteins dynamically regulates complex 215 
assembly and localization [18,19]. Particularly tyrosine phosphorylation of occludin and claudin-5 216 
C-terminus impacts their interaction with ZO-1 and cytoskeleton, and initiates protein internalization 217 
[20,21]. Immunoprecipitation was used to assess claudin-5 and occludin tyrosine phosphorylation 218 
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(pTyr) status after 24h exposure to hypoxia/OGD in a human brain microvascular endothelial cell 219 
line (hCMEC/D3) and primary rat brain EC. As expected increased phosphorylation of both 220 
proteins was seen in hypoxic hCMEC/D3. GSHee strongly suppressed hypoxia-induced (Fig. 7A 221 
and B) but not OGD-induced (Fig. 7B) occludin tyrosine phosphorylation compared to the normoxic 222 
condition, an observation also noted in primary isolated EC (Fig. 7D and E). In contrast, no effect 223 




Multiple studies suggest that stabilizing brain vascular function in patients with neurological 228 
disease could arrest or even reverse the course of brain disorders [2]. We are convinced that 229 
better understanding of the mechanisms by which perivascular cells support barrier function could 230 
provide new insight for future strategies aimed at modulating barrier function. This is the first study 231 
to prove the existence and importance of AC-EC metabolic cross-talk under different environmental 232 
conditions. We show that constitutive GSH shuttling from AC to EC is strongly increased during 233 
injury conditions and suppressing the shuttling significantly reduces AC protective effects and 234 
induces barrier dysfunction. Notably, exogenous GSH supplementation also preserved barrier 235 
stability in the absence of AC. Thus our data suggests that boosting/elevating GSH levels during 236 
disease could improve BBB functionality.  237 
GSH is a key regulator of redox-sensitive transcription factors and stress-sensing pathways that 238 
boosts the cellular metabolic systems defence against insult. Metabolomic profiling clearly revealed 239 
distinct and differential modulation of AC and EC GSH metabolic pathways. Despite being a high 240 
oxidative stress cell type [22], EC had relatively low GSH-related metabolite levels at baseline and 241 
seemingly exhausted - or perhaps could not replenish - key GSH metabolites during injury 242 
conditions. This progressive GSH metabolism shut down agrees with redox imbalance being a 243 
primary cause of EC dysfunction [23,24]. In contrast, AC had a highly activated GSH metabolism 244 
during stress conditions supporting observations that this pathway is well maintained under 245 
hypoxia and OGD [25,26].  246 
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Astrocytes play an important role in antioxidative metabolism and detoxification [5]. AC 247 
constitutively secrete GSH under baseline normoxic conditions and are reservoirs of this key anti-248 
oxidant and likely other important metabolites [6]. This characteristic can clearly benefit 249 
surrounding cells. Notably, GSH secretion was increased without influencing intracellular levels 250 
suggesting activated systems boost its release - although no GSH-specific transporter, exporter or 251 
importer, has been identified to date. GSH can however be co-transported with organic anions by 252 
different membrane proteins. Our data suggests MRP2 is most likely involved in AC GSH release 253 
during injury. 254 
Is GSH itself taken up directly by cells? Interestingly, intravenously injected GSH-coated 255 
nanoparticles targeted to EC for drug delivery were observed to successfully accumulate in brain 256 
tissue [27–29], but how they enter is not understood. In this study the fact that the isotope is 257 
detected in endothelial cells proves that labeled GSH (i.e. of astrocyte origin) is shuttled from AC to 258 
EC. Unfortunately, as our isotope labels GSH on sulfur and nitrogen but not specifically on cysteine, 259 
whether it can be directly absorbed remains debatable although most evidence does not support 260 
this scenario [30]. If indirectly taken up by EC various amino acid importers that transport GSH 261 
breakdown products should be taken into consideration. In neurons numerous importers indirectly 262 
participate in GSH absorption, including excitatory amino acid transporters (EAAT) 1-3 and Xc− 263 
antiporter (XCT) that regulate cysteine and glutamate levels to facilitate GSH synthesis [31,32]. 264 
Although we did not investigate this mechanism in detail, it was interesting that XCT mRNA levels 265 
(cysteine importer) were also induced in EC during injury conditions (data not shown). Utilizing this 266 
route would mean extracellular GSH catabolism is required [33]. Particularly, γ-glutamyl 267 
transpeptidase (GGT) might play a key role in releasing glutamate, cysteine and related peptides 268 
from AC GSH . Notably GGT has been detected in all BBB compartments including EC [34], 269 
pericyte [35] and AC [36]. Since injury conditions induced mRNA levels of AC GGT, as observed in 270 
various organs [37,38], we speculate that GGT-mediated GSH breakdown and XCT activation 271 
could jointly contribute to GSH recycling and shuttling to the EC compartment. For better insight a 272 
more detailed investigation of the precise mechanism is clearly warranted .  273 
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Paracrine metabolic processes clearly have a large part to play in regulating BBB stability. Even 274 
mild reduction of AC GSH secretion (10-20%) significantly increased barrier permeability implying 275 
perivascular metabolic disturbance may be a causative factor in worsening barrier integrity. It is 276 
highly probable that to ensure their own survival during harsh situations AC might withdraw their 277 
metabolic support leaving vascular EC to fend for themselves. Such a switch may explain the 278 
unexpected negative effects of AC on barrier stability observed during severe conditions [4,17,39]. 279 
In this regard GSH supplementation could significantly benefit vascular function. Indeed GSHee (a 280 
membrane permeable GSH analog) and NAC (a source of cysteine for GSH generation) 281 
administration prevented injury-induced EC permeability as seen in epithelial and hepatocyte 282 
studies [40,41]. We noted that GSH treatment prevented occludin tyrosine phosphorylation (pTyr), 283 
a modification well known to determine EC tight junction localization, complex stability and 284 
integration with regulatory proteins [42–44]. This data also aligns with occludin being a major target 285 
for hypoxia induced pTyr by c-Src tyrosine kinases [43,45]. Two different mechanisms may 286 
underlie GSH protection; 1) suppression of hypoxia-induced ROS imbalance to prevent the 287 
phosphorylation and 2) a non-ROS mediated pathway; perhaps directly activating protein tyrosine 288 
phosphatase (PTP) via glutathionylation [46,47]. The mechanisms at work during OGD are even 289 
more unclear as pTyr of both occludin and claudin-5 were unchanged by GSH exposure.  290 
Regardless, our data undoubtedly implies that enhancing EC GSH levels could improve redox 291 
homeostasis and suppress injury-induced vascular impairment. Although not yet considered for 292 
BBB protection, positive effects of boosting GSH has been demonstrated in some neurological-293 
related clinical trials. As GSH is unstable (easily oxidized) and has a very short half-life NAC, a 294 
cysteine analog that boosts GSH synthesis, has been the most commonly used enhancer. 295 
Intravenous injection of NAC successfully increased brain GSH levels in Parkinson's disease, 296 
Gaucher disease and healthy human brain as measured by Tesla magnetic resonance 297 
spectroscopy (ClinicalTrials.gov: NCT01427517 and NCT02445651) resulting in general patient 298 
improvement [48]. AD patients prescribed NAC over six months also showed significantly improved 299 
memory performance [49,50]. However as it is used at relatively high concentrations, NAC has 300 
quite a few unwanted side effects [51] and other studies did not observe positive effects 301 
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(Clinicaltrials.gov NCT00903695 and NCT01320527). As NAC is a precursor, compromised cell 302 
function during injury conditions may slow the processes needed for GSH synthesis. Indeed our 303 
study supports this view as the membrane permeable GSHee was considerably more effective 304 
than NAC. Notably, recent application of GSHee in a stroke MCAo mouse model also reduced 305 
infarct size and improved neurological outcome [52]. Thus a stable, cell permeable GSH analog 306 
could offer significant clinical advantages. 307 
To conclude, GSH shuttling from AC to EC supports brain vascular stability during insult and 308 
disturbance of this metabolic interaction likely compromizes barrier homeostasis. We thus 309 
advocate administration of GSH analogs to boost BBB function and sustain vascular health. Better 310 
understanding of the impact of other perivascular-derived metabolites, and paracellular crosstalk, 311 
could offer more opportunities to safeguard BBB integrity. 312 
 313 
 314 
MATERIAL AND METHODS 315 
Reagents  316 
TranswellsTM were obtained from Corning (Schiphol, The Netherlands). Lucifer yellow was 317 
purchased from Thermo Fisher. Protease inhibitor cocktail Set III from Calbiochem (Merck, 318 
Darmstadt, Germany). Oligofectamine™ Reagent	 and	 Pierce BCA Protein Assay were from 319 
Thermo Fisher Scientific Inc. (Rockford, IL). For Western blotting and immunofluorescence, 320 
antibodies directed against occludin, claudin-5, and ZO-1 were purchased from Invitrogen (Basel, 321 
Switzerland), β-actin antibody from Sigma–Aldrich (Buchs, Switzerland), and β-catenin antibody 322 
from Chemicon (Millipore, Billerica, MA). Anti-phosphotyrosine antibody agarose conjugate, clone 323 
4G10®, was purchased from Milipore. Secondary antibodies for Western blotting and 324 
immunofluorescence were obtained from Jackson ImmunoResearch (Suffolk, UK) or Invitrogen. 325 
For the glutathione (GSH) and ROS assay, 5,5-Dithio-Bis-(2-Nitrobenzoic acid) (DTNB) and 2’,7’-326 
Dichlorofluorescin diacetate were obtained from Sigma–Aldrich (Buchs, Switzerland). Isotopic 327 
labeled 34S15N-cysteine was designed and synthesized by Dr. T. Sawa (Graduate School of 328 
Medical Sciences, Kumamoto University) [53]. γ-glutamyl cysteine ligase catalytic subunit (GCLc) 329 
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siRNA (ON-TARGET plus SMART pool) and negative control siRNA (ON-TARGET plus non-330 
targeting pool) were purchased from Dharmacon.  331 
 332 
Primary cell isolation and cell culture 333 
All cell culture media and reagents were obtained from Gibco® (Life Technologies, Zug, Switzerland) 334 
and Sigma-Aldrich. Primary rat astrocytes (AC) were isolated from neonatal pups as described [54] 335 
then cultured in DMEM supplemented with 10% FBS and 50 µg/ml gentamycin sulfate on gelatin-336 
coated dishes and used after the first passage. Primary rat brain microvascular endothelial cells 337 
(EC) were isolated from 8-10 week old male Wistar rats as previously described [55]. EC reached 338 
100% confluence after 7 days culture and were used without passaging. The human cerebral 339 
microvascular endothelial cell line HCMEC/D3 was used for immunoprecipitation experiments. 340 
HCMEC/D3 were cultivated in Endo GROTM-MV (Millipore) medium containing 5% FBS on 341 
collagen-coated culture dishes.  342 
 343 
Co-culture methodology  344 
Two different co-culture systems were employed in this study: 1) Contact co-culture model. Primary 345 
EC cells were seeded on the upper side of collagen-coated TranswellsTM till confluent with AC 346 
seeded on the lower side, both at a density of 0.5 x 106 cells/insert. Co-cultures were incubated in 347 
DMEM with 10% calf serum (with or without glucose) for 24h. After exposure the cell lysates were 348 
collected separately for liquid chromatography-Mass Spectrometry (LC-MS) analysis. 2) Non-349 
contact co-culture model. As primary cells are very sensitive to trypsin treatment, this model was 350 
used to bypass lifting cells after siRNA transfection. AC were cultured at a density of 0.5 x 106 351 
cells/well in 24 well plates whereas EC were cultured as described in the model above. The inserts 352 
with EC monolayers were then transferred to the 24-well plates containing transfected AC to 353 
initiate the co-culture. These co-cultures were kept in DMEM with 10% calf serum (with or without 354 
glucose) for 48h then used for permeability assays.   355 
 356 
O2 deprivation and ischemic treatment  357 
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O2 deprivation experiments were carried out in a purpose-built hypoxic glove-box chamber (InVivO2 358 
400, Ruskinn Technologies, Pencoed, UK) maintained at 37°C with 5% CO2. O2 concentration was 359 
constantly monitored with an internal O2 sensor. Cells were exposed to normoxia (Nx, 21% O2,), 360 
hypoxia (Hx, 1% O2), oxygen and glucose deprivation (OGD, 1% O2 without glucose) and severe 361 
OGD (0.2% O2 without glucose) for 24h/48h.  362 
 363 
Untargeted LC-MS measurements 364 
Non-targeting mass spectrometry measurements and analyses were conducted in cooperation with 365 
the Functional Genomics Center Zurich (FGCZ), University of Zurich. Sample preparation and 366 
measurements were performed using a nanoACQUITY system coupled to a Synapt G2HD mass 367 
spectrometer (Waters Corp., Milford, USA) as previously described (Huang et al, in submission). 368 
Chromatographic separation of metabolites was performed on a 0.2 µm x 150 mm BEH amide 369 
column using a 10 minutes linear gradient of 90% to 50% acetonitrile, 0.5 mM ammonium acetate, 370 
pH 9. All analyses were done in negative mode using 1.2 kV capillary voltage, 30 V sampling cone 371 
voltage and 3 V extraction cone voltage. The source temperature was set to 100°C and Nano Flow 372 
Gas, i.e. sheet gas flow, was applied.  373 
 374 
Data analysis and processing 375 
Waters raw data were first converted to centroid mode and further processed into vendor 376 
independent netCDF format using DataBridge (Masslynx, Waters Corp.). Untargeted metabolomics 377 
data matrix comprising of accurate mass/retention time information, and ion counts for each 378 
sample were calculated using the data processing tool cosmiq [56]. Signal-to-noise ratio (SNR) of 379 
mass peak detection was set to 3, SNR for chromatographic peak detection was set to 10 and a 380 
m/z bin size of 0.003 Da was chosen as parameters for cosmiq. For metabolite annotation, the 381 
resulting list was first matched to a list of metabolites with known retention time and mass. For 382 
additional annotation of unknown metabolites, the list of accurate masses was matched to the 383 




Data normalization strategy  387 
To be able to compare the relative metabolite quantities between the different treatments and cell 388 
types, we performed a normalization approach according to the sum of all detected metabolite ion 389 
counts as previous (Huang et al. in press). One of the Nx EC samples was randomly chosen as 390 
reference and the normalized ion intensity for each metabolite was calculated by dividing the 391 
observed ion intensity by the factor is/ ir, where is is the summed ion intensity for each 392 
individual sample and ir is the summed ion intensity of the reference sample. 393 
 394 
Oxidative stress detection and GSH measurement  395 
ROS formation reflecting intracellular oxidative stress was quantified by fluorometric techniques 396 
based on 2’,7’-Dichlorofluorescin diacetate (DCF) oxidation according to the manufacturer’s 397 
instruction (Sigma-Aldrich). GSH measurement was performed using DTNB (5,5’-dithio-bis (2-398 
nitrobenzoic acid)) as published (Bogdanova et al., 2005). Briefly, intracellular GSH levels were 399 
measured from the cell lysates harvested in cell lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton 400 
X-100, 1% NP-40) supplemented with protease inhibitor cocktail (Calbiochem, Darmstadt, 401 
Germany), 1 mM sodium orthovanadate, 1 mM dithiothreitol, 0.5 mM phenylmethansulfonyl fluoride 402 
and 1 mM EDTA. Total protein concentrations were measured using	Pierce BCA protein assay and 403 
50 µg was measured in a 96-well format. Extracellular GSH was detected in 100 µL culture media 404 




Permeability assay  409 
Permeability assays were performed on TranswellsTM with confluent primary EC as previously 410 
described [17]. Fresh medium containing the fluorescent dye lucifer yellow was added to the upper 411 
compartment. At 0, 15, 30, 45 min aliquots were taken from the bottom compartment. Sample 412 
fluorescence was measured with a plate reader (FLx800, Biotek Instruments, Winooski, VT). A 413 
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clearance slope was established from the measurements obtained at different timepoints and used 414 
to calculate permeability coefficient values (Pe) (Rist et al., 1997).  415 
 416 
Immunostaining  417 
Primary ECs were grown on coverslips coated with collagen IV. After hypoxic and ischemic 418 
exposure cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100 in PBS and 419 
incubated with occludin (1:100, Invitrogen), claudin-5 (1:100, Invitrogen), -catenin (1:100, 420 
Chemicon). 	Cell nuclei were counterstained with DAPI (4’,6-Diamidin-2-phenylindol). Pictures were 421 
taken using an inverted fluorescence microscope coupled to an 8-bit CCD camera (Axiocam HR, 422 
Carl Zeiss) and processed using ImageJ software. 423 
 424 
Immunoblotting  425 
Cells were washed with ice-cold PBS and homogenized in cell lysis buffer (50 mM Tris, 150 mM 426 
NaCl, 1% Triton X-100, 1% NP-40) supplemented with protease inhibitor cocktail. After 427 
measurement with Pierce BCA protein assay 30 µg protein were separated on denaturing SDS-428 
Page and transferred to a nitrocellulose membrane. Membranes were blocked at room 429 
temperature in 5% non-fat dried milk or 5% BSA and subsequently incubated overnight at 4°C in 430 
primary antibodies against -actin (1:5000), occludin (1:500) and claudin-5 (1:300). Membranes 431 
were washed with 0.1% Tween-20 in TBS or PBS then incubated with horseradish peroxidase 432 
(HRP) conjugated secondary antibody. Band detection was performed and visualized using a 433 
luminescent image analyzer LAS-3000 (Fujifilm, Dielsdorf, Switzerland). Blot quantification (using 434 
-actin as loading controls) was performed using ImageJ software (NIH, Bethesda, USA). 435 
 436 
Immunoprecipitation  437 
Protein (1 mg) was suspended in IP buffer (50mM Tris–HCl pH 7.4, 150mM EDTA and 0.5% NP-438 
40, 1mM NaVO3, 1mM PMSF) then 30µl of anti-phosphotyrosine antibody agarose conjugate 439 
(4G10) was added. After 4h incubation at 4˚C in a circular rotator samples were centrifuged (1000 440 
rpm for 1 min) then the supernatant removed and the beads washed 3 times with IP buffer. 441 
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Captured proteins were eluted by incubating at 80˚C in 2x Laemmli buffer then run on a 10% SDS–442 
Page gel. 443 
 444 
Metabolite extraction 445 
Cell pellets were collected and washed (75 mM Ammonium Carbonate, pH 7.4), then incubated 446 
with cold 40:40:20 acetonitrile:methanol:water mixture for 10 min to quench the metabolism. 447 
Supernatants were stored at –80˚C. 448 
  449 
Measurement of Isotopic labeled metabolites 450 
TOF-MS measurements and analyses were followed the procedure of Fuhrer et al. [57]. Analysis 451 
was performed on a platform consisting of an Agilent Series 1200 LC pump coupled to a Gerstel 452 
MPS3 autosampler and an Agilent 6550 Series Quadrupole Time-of-flight mass spectrometer 453 
(Agilent, Santa Clara, CA) equipped with an electrospray source operated in negative mode [57]. 454 
Spectra were recorded in profile mode from m/z 50 to 1000 with a frequency of 1.4 spectra/s for 455 
0.48 min using the highest resolving power (4 GHz HiRes). Source temperature was set to 325 °C.  456 
 457 
Data Processing and normalization of Isotopic labeled metabolites 458 
All data processing and analysis steps were performed with Matlab R2010b (The Mathworks, 459 
Natick). More details on data processing, ion annotation, and statistical analysis are shown in the 460 
supplementary data. We present the GSH M+3/M ratio based on its intracellular labeled 461 
percentage in EC to enable us to largely exclude the influence of passive release.  462 
 463 
siRNA transfection  464 
Oligofectamine™ Reagent was mixed with 100 µM siRNA and used to transfect ACs according to 465 
the manufacturer's instructions. After transfection, knockdown efficiency was confirmed using 466 




All results are expressed as mean±SD from a minimum of three independent experiments. 470 
Statistical significance using GraphPad Prism 7 software (La Jolla, CA) was assessed by Students 471 
T-test or one-way ANOVA for comparison of different time points within a group and two-way 472 
ANOVA for comparison between different groups. A P-value below 0.05 was considered significant. 473 
 474 
 475 
FIGURE LEGENDS 476 
Fig. 1: Changes in glutathione-related metabolites during injury conditions  477 
Levels of metabolites that participate in glutathione (GSH) metabolism in rat brain primary 478 
astrocyte (AC) and endothelial cell (EC) were measured by LC-MS after exposure to oxygen 479 
deprivation (1% O2 and  0.2% O2) combined with or without glucose (Glc) withdrawal for 24h. (A) 480 
Heatmap shows the relative activity of the major GSH-related metabolites comparing the two cell 481 
types under normoxia (Nx). (B) Heatmap of GSH metabolic alterations during injury was generated 482 
by comparison with their Nx control with increased metabolite level in red and decreased 483 
metabolite level in blue. (C-E) Ion counts of three GSH metabolism indicators, γ-glutamyl-cysteine 484 
(C), GSH (D) and GSH disulfide (E), during injury is presented separately. Hypoxia (Hx, 1% O2 with 485 
glucose) and OGD (1% O2 without glucose). The metabolite intensities were normalized to total ion 486 
counts. The -Log2(P value) for each metabolite was calculated using unpaired T-test. *P<0.05; 487 
One-way ANOVA compared to Nx. #P<0.05, ##P<0.01, ###P<0.001; Two-way ANOVA, compared to 488 
astrocytes (AC) in the same condition. Mean ± SD. n = 4.  489 
 490 
Fig. 2: Oxidative homeostasis is stable in AC but not EC 491 
(A and B) Oxidative stress measurements were performed in primary AC (A) and EC (B) exposed 492 
to hypoxia (Hx, 1% O2 with glucose) and OGD (1% O2 without glucose). Nx, 21% O2 with glucose 493 
group was used as control. *P<0.05, **P<0.01, ***P<0.001; Two-way ANOVA compared to Nx at 494 
the same time point. Mean ± SD. n = 3. 495 
    496 
Fig. 3: Injury increases GSH secretion by AC 497 
	 19
(A and B) Changes in intracellular and extracellular GSH levels in primary AC after 6h, 16h and 498 
24h Hx and OGD were measured in cell lysates (A) and culture media (B) respectively.  499 
Concentrations were normalized to either 1 mg total protein or 1 mL media to facilitate comparison 500 
between the different conditions and cell type. *P<0.05, **P<0.01, ***P<0.001; two-way ANOVA 501 
compared to Nx baseline. #P<0.05; Two-way ANOVA, compared to injury 6h baseline. Mean ± SD. 502 
n=6. 503 
 504 
Fig. 4: GSH is constantly shuttled from AC to EC 505 
To investigate if EC take up AC-derived GSH, a stable isotope labelling approach was combined 506 
with Time-of-Flight Mass Spectrometry (TOF-MS) to specifically track AC synthesized GSH. (A) 507 
The schematic shows the experimental setup. Endogenous GSH was depleted by incubating with 508 
L-Cys/Met free media for 24h. 34S15N-cysteine was employed to stimulate AC endogenous 34S15N-509 
GSH generation. Isotope-labeled AC were co-cultured with EC under different conditions for 24h 510 
then cell lysates were analyzed by TOF-MS. (B) Levels of intracellular 34S15N-GSH was measured 511 
in untreated AC lysate (baseline) and after 24h isotope stimulation. (C) After co-culture, levels of 512 
labeled GSH in EC lysates were measured. *P<0.05, **P<0.01, ***P<0.001; Student’s T- test 513 
compared to baseline. Mean ± SD. n=4  514 
 515 
Fig. 5: Paracrine GSH shuttling is crucial for barrier maintenance during injury  516 
(A) AC were transfected with GCL small Interfering RNA (siGCL). A representative immunoblot 517 
after 48h transfection shows normoxic GCL expression levels. (B) The rate of GSH release by 518 
normoxic AC after GCL knockdown was measured post transfection at 24h and 48h. (C) 519 
Permeability of the EC barrier after co-culture with transfected AC under different conditions for 520 
48h was measured by lucifer yellow flux. **P<0.01, compared to Nx siCTRL. #P<0.05, ##P<0.01; 521 
Student’s T-test compared to injury control (siCTRL). n=8. 522 
 523 
Fig. 6: Boosting EC GSH levels prevents injury-induced BBB breakdown   524 
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Primary EC monolayers were either untreated (UNT) or exposed to GSH compounds and exposed 525 
to hypoxia/OGD for 48h. GSH enhancers (5mM NAC and 5mM GSHee) and GSH synthetase 526 
inhibitor (200µM BSO) were applied. (A and B) EC barrier leakage was measured under Hx and 527 
OGD using lucifer yellow. (C and D) Representative immunofluorescent images of claudin-5 and β-528 
catenin localization in EC. Note the disconnection and delocalization of junctions in areas marked 529 
by arrows. Asterisks indicate inter-EC gap formation and holes. *P<0.05; One-way ANOVA 530 
compared to Nx baseline. #P<0.05, ##P<0.01, ###P<0.001; Two-way ANOVA, compared to injury 531 
untreated (UNT). Mean ± SD. n = 5.  532 
 533 
Fig. 7: Exogenous GSH suppresses occludin tyrosine phosphorylation 534 
Two different cell models (human brain microvascular EC cell line (hCMEC/D3) and primary EC) 535 
were treated with GSHee prior to hypoxic or ischemic exposure for 24h. (A) Immunoprecipitation 536 
(I.P) using phospho-tyrosine conjugated (p-Tyr) beads was performed followed by immunoblot 537 
analysis of tight junction proteins in hCMEC/D3. (B and C) Densitometric quantification of pTyr-538 
occludin (B) and pTyr-claudin (C) was subsequently carried out. (D and E) Similar modulations 539 
were further confirmed in primary EC, shown in the representative immunoblots (D) and 540 
densitometric quantification (E). I.P pTyr blot shows the pTyr protein level whereas supernatant 541 
blot shows the unpulled protein. β-actin as a loading control. #P<0.05, ##P<0.01; one-way ANOVA 542 
compared to Hx baseline. n=5 in hCMEC/D3; n=4 in primary EC.  543 
 544 
 545 
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I.P pTyr blot: Occludin
























































































































































































































Fig. S1: Injury induces MRP2 transporter and extracellular stabilizer expression
AC lysates were collected after 6h/24h exposure. a, c Using quantitative PCR the mRNA level of 
multidrug resistance-associated protein 2 (MRP2) and g-glutamyl transferase (GGT) after 6h 
exposure were assessed. MRP2 and GGT protein expression in AC cell lysates with 24h 
exposure were assessed by immunoblot. b, c Densitometric quantification of MRP2 protein and 
GGT protein. *P<0.05, **P<0.01, ***P<0.001; One-way ANOVA compared to Nx baseline. Mean 
SD. n=4
Fig. S2
Fig S2: Labeled GSH in AC is diluted after 48h incubation
Isotope-stimulated AC were co-cultured with EC for 24h under different conditions. At experimental end, 
AC cell lysates were analyzed by TOF-MS. Intracellular 34S15N-GSH levels in AC were analyzed based 






















































































Fig. S3: GSH-deficient AC lose the ability to prevent injury-induced BBB opening
After 48h GCL siRNA transfection, AC were co-cultured with EC and exposed to hypoxia (Hx)
and OGD for 48h. At the end of experiment, barrier leakage was measured using lucifer yellow.
Fold changes of permeability were compared to Nx UNT. #P<0.05, ##P<0.01; Student’s T-test
compared to injury control (siCTRL). n=8.
Fig. S4
Fig. S4: GSH enhancer does not impact cell survival
hCMEC/D3 were exposed to 48h hypoxia/OGD. Cell nuclei were stained by DAPI and cell counting
was performed by automatic cell counter. ***P<0.001; Two-way ANOVA compared to Nx baseline.
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